Ondansetron HCl hydrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H100676

CAS#: 103639-04-9 (HCl hydrate),

Description: Ondansetron is a highly selective serotonin 5-HT3 receptor antagonist, with low affinity for dopamine receptors. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. in vitro studies confirm that Ondansetron inhibits AChE and BChE by non-competitive and mixed inhibition, respectively, with IC50 values 33 µM (AChE) and 2.5 µM (BChE). Ondansetron showed activity for preventing of ovarian hyperstimulation syndrome


Chemical Structure

img
Ondansetron HCl hydrate
CAS# 103639-04-9 (HCl hydrate),

Theoretical Analysis

Hodoodo Cat#: H100676
Name: Ondansetron HCl hydrate
CAS#: 103639-04-9 (HCl hydrate),
Chemical Formula: C18H24ClN3O3
Exact Mass: 365.15
Molecular Weight: 365.858
Elemental Analysis: C, 59.09; H, 6.61; Cl, 9.69; N, 11.49; O, 13.12

Price and Availability

Size Price Availability Quantity
1g USD 250 2 Weeks
5g USD 650 2 Weeks
Bulk inquiry

Related CAS #: 99614-02-5 (free base)   99614-01-4 (HCl)   103639-04-9 (HCl hydrate),  

Synonym: GR 38032F; GR-38032F;GR38032F;GRC50775; GRC-50775; GRC 50775; SN307; Ondansetron HCl hydrate

IUPAC/Chemical Name: 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1- yl)methyl]-4H-carbazol-4-one, monohydrochloride, dihydrate

InChi Key: VRSLTNZJOUZKLX-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

SMILES Code: O=C1C(CN2C=CN=C2C)CCC(N3C)=C1C4=C3C=CC=C4.[H]Cl.[H]O[H].[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: The 5-HT3 receptors are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema in the medulla. Serotonin is released by the enterochromaffin cells of the small intestine in response to chemotherapeutic agents and may stimulate vagal afferents (via 5-HT3 receptors) to initiate the vomiting reflex. It is thought that ondansetron's antiemetic action is mediated mostly via antagonism of vagal afferents with a minor contribution from antagonism of central receptors.

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 365.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gholami A, Minai-Tehrani D, Eriksson LA. In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor. Sci Rep. 2023 Jan 12;13(1):643. doi: 10.1038/s41598-022-27149-z. PMID: 36635365; PMCID: PMC9837033.


2: Mehta MV, Chudasama PA, Baria T. To Compare the Effectiveness of Granisetron Versus Ondansetron to Control Nausea and Vomiting During Lower Segment Cesarean Section Under Subarachnoid Block. Anesth Essays Res. 2022 Jul-Sep;16(3):378-380. doi: 10.4103/aer.aer_86_22. Epub 2022 Dec 9. PMID: 36620101; PMCID: PMC9813993.


3: Bakırcı Ş, Sağsöz N, Devrim T, Şahin Y, Bulanık M, Gözüyukarı H. Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model. Gynecol Endocrinol. 2022 Dec 29:1-4. doi: 10.1080/09513590.2022.2163233. Epub ahead of print. PMID: 36579847.


4: Firew E, Huang H, Anand A, Asfaw YA, Parikh C, Khan HR. Ondansetron-induced pseudoallergy with non-ischemic myocardial injury: A rare case report of Kounis syndrome. Clin Case Rep. 2022 Dec 22;10(12):e6781. doi: 10.1002/ccr3.6781. PMID: 36578798; PMCID: PMC9780426.


5: Li H, Jia Y, Liu C. Retraction notice to "Pluronic® F127 stabilized reduced graphene oxide hydrogel for transdermal delivery of ondansetron: Ex vivo and animal studies" [Colloids Surf. B Biointerfaces, 195, (2020), 111259]. Colloids Surf B Biointerfaces. 2022 Dec 24;222:113062. doi: 10.1016/j.colsurfb.2022.113062. Epub ahead of print. PMID: 36571979.


6: Hou XM, Chen YJ, Lai L, Liu K, Shen QH. Ondansetron Reduces the Incidence of Hypotension after Spinal Anaesthesia: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2022 Dec 19;15(12):1588. doi: 10.3390/ph15121588. PMID: 36559039; PMCID: PMC9787671.


7: Mansour M, Nasr M, Ahmed-Farid OAH, Ahmed RF. Intranasal ondansetron microemulsion counteracting the adverse effects of cisplatin: animal study. Pharmacol Rep. 2022 Dec 14. doi: 10.1007/s43440-022-00435-3. Epub ahead of print. PMID: 36517694.


8: Abdulhussain AS. Combination of dexamethasone and ondansetron in prophylaxis nausea and vomiting in gynecological operation. J Popul Ther Clin Pharmacol. 2022 Dec 3;29(4):e150-e157. doi: 10.47750/jptcp.2022.984. PMID: 36464494.


9: Ali HG, ELatief NA. Comparison of Prophylactic Phenylephrine Infusion Versus Intravenous Ondansetron on Hypotension During Spinal Anesthesia for Cesarean Section. Anesth Essays Res. 2022 Apr-Jun;16(2):226-230. doi: 10.4103/aer.aer_48_22. Epub 2022 Sep 19. PMID: 36447915; PMCID: PMC9701336.


10: Reis ACC, Jorge BC, Stein J, Moreira SDS, Manoel BM, Aquino AM, Valente LC, Kassuya CAL, Scarano WR, Arena AC. Safety evaluation of ondansetron after gestational exposure on male reproductive parameters in rats. Regul Toxicol Pharmacol. 2023 Jan;137:105302. doi: 10.1016/j.yrtph.2022.105302. Epub 2022 Nov 26. PMID: 36442580.


11: Rezvani Kakhki B, Ghasemi T, Vafadar Moradi E, Abbasi Shaye Z, Mousavi SM. Aromatherapy with Isopropyl Alcohol versus Intravenous Ondansetron in Management of Mild Brain Trauma Nausea and Vomiting; a Randomized Clinical Trial. Arch Acad Emerg Med. 2022 Oct 31;10(1):e87. doi: 10.22037/aaem.v10i1.1792. PMID: 36426172; PMCID: PMC9676696.


12: Shayan M, Eslami F, Khosravi A, Rashidian A, Jafari RM, Maroufi SF, Golroudbari HT, Dehpour AR. The Possible Protective Effects of Ondansetron and Tropisetron on Optic Nerve Crush Injury in Rats. Drug Res (Stuttg). 2022 Nov 24. doi: 10.1055/a-1969-4600. Epub ahead of print. PMID: 36423625.


13: Feiz Disfani H, Kamandi M, Hoseini SB, Shirazi N, Panahi M. Nausea control in mild head trauma patients: Effectiveness of metoclopramide and ondansetron in the emergency department in a double-blind study. Caspian J Intern Med. 2022 Fall;13(4):699-704. doi: 10.22088/cjim.13.4.699. PMID: 36420343; PMCID: PMC9659822.


14: Black K, Brenn BR, Gaedigk A, Wanderer JP, Van Driest SL. Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron. Clin Transl Sci. 2022 Nov 9. doi: 10.1111/cts.13447. Epub ahead of print. PMID: 36350309.


15: Wu M, Cheng Z, Le AT, Tan Y, Peltz G. Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain. Clin Transl Sci. 2022 Oct 28. doi: 10.1111/cts.13440. Epub ahead of print. PMID: 36305236.


16: Vashishth S, Lal J, Bangarwa N, Wadhwani J, Smriti M. Efficacy of Variable Doses of Prophylactic Intravenous Ondansetron in Attenuating Spinal Induced Hypotension in Parturients Undergoing Caesarean Delivery: A Randomised Control Trial. Cureus. 2022 Sep 22;14(9):e29440. doi: 10.7759/cureus.29440. PMID: 36299981; PMCID: PMC9587515.


17: Wongyingsinn M, Peanpanich P, Charoensawan S. A randomized controlled trial comparing incidences of postoperative nausea and vomiting after laparoscopic cholecystectomy for preoperative intravenous fluid loading, ondansetron, and control groups in a regional hospital setting in a developing country. Medicine (Baltimore). 2022 Oct 21;101(42):e31155. doi: 10.1097/MD.0000000000031155. PMID: 36281094; PMCID: PMC9592396.


18: Das S, Kumar A, Gupta A, Kumar A. A Randomised Controlled Trial to Compare the Effect of Ramosetron and Ondansetron in Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynaecological Procedures. Cureus. 2022 Sep 15;14(9):e29200. doi: 10.7759/cureus.29200. PMID: 36258972; PMCID: PMC9569150.


19: Somsundar RG, Shivakumar G, Santhosh MCB, Krishna K. A Comparative Clinical Study of Methylprednisolone with Ondansetron versus Ramosetron in Preventing Postoperative Nausea and Vomiting in Patients Undergoing Middle-Ear Surgeries. Anesth Essays Res. 2022 Jan-Mar;16(1):60-64. doi: 10.4103/aer.aer_2_22. Epub 2022 Jun 27. PMID: 36249137; PMCID: PMC9558658.


20: Li C, Cui W, Song P, Liu W, Wang X, Yang Q. Effect of ondansetron for preventing postoperative nausea and vomiting after breast cancer surgery. Am J Transl Res. 2022 Sep 15;14(9):6689-6695. PMID: 36247242; PMCID: PMC9556477.